Literature DB >> 3592781

Correlation of immunoglobulin and C reactive protein levels in ankylosing spondylitis and rheumatoid arthritis.

K M Sanders, A Hertzman, M R Escobar, B H Littman.   

Abstract

Serum C reactive protein (CRP), IgG, and IgA levels were measured in 22 patients with ankylosing spondylitis (AS) and in 20 patients with rheumatoid arthritis (RA) to study the regulation of these proteins in inflammatory disease states. In both RA and AS the mean CRP, IgG, and IgA levels were raised above normal values. Although IgA and CRP levels showed a significant positive correlation in RA (r = 0.53, p = 0.02), there was no correlation between these values in AS (r = 0.24, p = 0.29). The difference in correlation coefficients between the AS and RA groups was significant at a p = 0.05 level. In RA the raised IgA levels may be another manifestation of the acute phase response, as shown by the good correlation between IgA and CRP in that disease. In AS, however, the IgA levels, although raised, do not correlate with CRP levels, suggesting that the mechanism of increase of IgA in the two diseases is different. Gut mediated immune stimulation has been proposed as a cause of raised IgA levels in AS.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3592781      PMCID: PMC1002118          DOI: 10.1136/ard.46.4.273

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  26 in total

1.  The assessment of rheumatoid arthritis. A study based on measurements of the serum acute-phase reactants.

Authors:  B McConkey; R A Crockson; A P Crockson
Journal:  Q J Med       Date:  1972-04

2.  Serum levels of IgG, IgM, and IgA in rheumatoid arthritis.

Authors:  E M Veys; H E Claessens
Journal:  Ann Rheum Dis       Date:  1968-09       Impact factor: 19.103

3.  Serum and synovial fluid proteins in rheumatoid arthritis and degenerative joint diseases.

Authors:  W Pruzanski; M L Russell; D A Gordon; M A Ogryzlo
Journal:  Am J Med Sci       Date:  1973-06       Impact factor: 2.378

4.  Circulating immune complexes in ankylosing spondylitis.

Authors:  H Deicher; A Ebringer; S Hildebrand; A Kemper; H Zeidler
Journal:  Br J Rheumatol       Date:  1983-11

Review 5.  Reiter's syndrome and reactive arthritis in perspective.

Authors:  A Keat
Journal:  N Engl J Med       Date:  1983-12-29       Impact factor: 91.245

6.  Serum IgG, IgM, and IgA levels in ankylosing spondylitis.

Authors:  E M Veys; M van Leare
Journal:  Ann Rheum Dis       Date:  1973-11       Impact factor: 19.103

7.  Correlation of clinical parameters of disease activity in rheumatoid arthritis with serum concentration of C-reactive protein and erythrocyte sedimentation rate.

Authors:  R K Mallya; F C de Beer; H Berry; E D Hamilton; B E Mace; M B Pepys
Journal:  J Rheumatol       Date:  1982 Mar-Apr       Impact factor: 4.666

8.  Secretory IgA: immune defence pattern in ankylosing spondylitis and klebsiella.

Authors:  M Calguneri; L Swinburne; R Shinebaum; E M Cooke; V Wright
Journal:  Ann Rheum Dis       Date:  1981-12       Impact factor: 19.103

9.  Acute-phase proteins and serum immunoglobulins in ankylosing spondylitis.

Authors:  M R Laurent; G S Panayi
Journal:  Ann Rheum Dis       Date:  1983-10       Impact factor: 19.103

10.  IgA antibodies to Klebsiella pneumoniae in ankylosing spondylitis.

Authors:  A K Trull; R Ebringer; G S Panayi; D Colthorpe; D C James; A Ebringer
Journal:  Scand J Rheumatol       Date:  1983       Impact factor: 3.641

View more
  10 in total

Review 1.  Small intestinal mucosal protection mechanisms and their importance in rheumatology.

Authors:  S O'Mahony; A Ferguson
Journal:  Ann Rheum Dis       Date:  1991-05       Impact factor: 19.103

2.  Increased levels of serum IgA as IgA1 monomers in ankylosing spondylitis.

Authors:  H Hocini; S Iscaki; C Benlahrache; L Vitalis; X Chevalier; B Larget-Piet; J P Bouvet
Journal:  Ann Rheum Dis       Date:  1992-06       Impact factor: 19.103

3.  Serum secretory immunoglobulins in ankylosing spondylitis.

Authors:  D Wendling; J M Didier; E Seilles
Journal:  Clin Rheumatol       Date:  1996-11       Impact factor: 2.980

4.  Serum IgA, acute phase proteins, and glycosylation of alpha 1-acid glycoprotein in ankylosing spondylitis.

Authors:  A Mackiewicz; M A Khan; T L Reynolds; S van der Linden; I Kushner
Journal:  Ann Rheum Dis       Date:  1989-02       Impact factor: 19.103

5.  Prenatal toxoplasmosis antibody and childhood autism.

Authors:  Marisa N Spann; Andre Sourander; Heljä-Marja Surcel; Susanna Hinkka-Yli-Salomäki; Alan S Brown
Journal:  Autism Res       Date:  2016-11-22       Impact factor: 5.216

6.  Sulphasalazine in ankylosing spondylitis. A radiological, clinical and laboratory assessment.

Authors:  H G Taylor; E J Beswick; P T Dawes
Journal:  Clin Rheumatol       Date:  1991-03       Impact factor: 2.980

7.  Assessment of clinical efficacy and safety in a randomized double-blind study of etanercept and sulfasalazine in patients with ankylosing spondylitis from Eastern/Central Europe, Latin America, and Asia.

Authors:  Nemanja Damjanov; Waleed Al Shehhi; Feng Huang; Sameer Kotak; Ruben Burgos-Vargas; Khalid Shirazy; Eustratios Bananis; Annette Szumski; Lyndon J Q Llamado; Ehab Mahgoub
Journal:  Rheumatol Int       Date:  2016-03-11       Impact factor: 2.631

8.  Anti-agalactosyl IgG antibody in ankylosing spondylitis and psoriatic arthritis.

Authors:  Chen-Liang Chou; Min-Jung Wu; Chia-Li Yu; Ming-Chi Lu; Song-Chou Hsieh; Tsai-Hung Wu; Chung-Tei Chou; Chang-Youh Tsai
Journal:  Clin Rheumatol       Date:  2010-03-14       Impact factor: 2.980

9.  Circulating levels of sialic acid and glycosaminoglycans: a diagnostic test for ankylosing spondylitis.

Authors:  A K Susheela; T K Das; J S Khurana; A Jayaswal; P K Dave
Journal:  Ann Rheum Dis       Date:  1988-10       Impact factor: 19.103

10.  Higher Levels of Secretory IgA Are Associated with Low Disease Activity Index in Patients with Reactive Arthritis and Undifferentiated Spondyloarthritis.

Authors:  Fabián Salas-Cuestas; Wilson Bautista-Molano; Juan M Bello-Gualtero; Ivonne Arias; Diana Marcela Castillo; Lorena Chila-Moreno; Rafael Valle-Oñate; Daniel Herrera; Consuelo Romero-Sánchez
Journal:  Front Immunol       Date:  2017-04-27       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.